| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Inhibitor Therapeutics, Inc. (INTI) has 0 insiders with recent SEC Form 4 filings, including 4 buys and 4 sells. INTI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2019 | Hasara Garrison J. | CFO And Treasurer | Buy | 13,500 | $0.07 | $945.00 | +0.3% | |
| Aug 30, 2018 | Hasara Garrison J. | CFO And Treasurer | Sell | 100,000 | $0.27 | $27,000.00 | -2.5% | |
| Dec 19, 2017 | Mayne Pharma Ventures Pty Ltd | 10% Owner | Buy | 600,000 | $0.00 | - | +0.3% | |
| Dec 19, 2017 | Cross Stefan | Director | Buy | 600,000 | $0.00 | - | -100% | |
| Jun 30, 2017 | Hedgepath, LLC | 10% Owner | Sell | 2,500,000 | $0.00 | - | -3.0% | |
| Jun 15, 2016 | Odonnell Francis E Jr | Executive Chairman | Sell | 2,560,000 | $0.00 | - | -18.3% | |
| Jun 15, 2016 | Hedgepath, LLC | 10% Owner | Sell | 2,560,000 | $0.00 | - | -3.0% | |
| Sep 10, 2015 | Odonnell Francis E Jr | Executive Chairman | Buy | 20,000,000 | $0.00 | - | New |